Vaxxinity, Inc. (VAXX)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Feb 2, 2026, 12:48 PM EST
Vaxxinity Employees
As of December 31, 2023, Vaxxinity had 65 total employees, including 57 full-time and 8 part-time employees. The number of employees decreased by 24 or -26.97% compared to the previous year.
Employees
65
Change (1Y)
-24
Growth (1Y)
-26.97%
Revenue / Employee
n/a
Profits / Employee
-$933,344
Market Cap
12.68K
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2023 | 65 | -24 | -26.97% | 57 | 8 |
| Dec 31, 2022 | 89 | 0 | - | 87 | 2 |
| Dec 31, 2021 | 89 | - | - | 89 | 0 |
| Sep 30, 2021 | 75 | - | - | 75 | 0 |
| Jun 30, 2021 | 75 | - | - | 75 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Scorpius Holdings | 91 |
| Syros Pharmaceuticals | 68 |
| Trevena | 23 |
| America Great Health | 5 |
| Virpax Pharmaceuticals | 2 |
Vaxxinity News
- 1 year ago - Vaxxinity UB-312 Parkinson's Trial Results Published in Nature Medicine - GlobeNewsWire
- 1 year ago - Vaxxinity Issues Shareholder Letter - GlobeNewsWire
- 1 year ago - Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock - GlobeNewsWire
- 2 years ago - Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting - GlobeNewsWire
- 2 years ago - Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 2 years ago - Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024 - GlobeNewsWire
- 2 years ago - Vaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published - GlobeNewsWire
- 2 years ago - Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024 - GlobeNewsWire